Study finds no support for link between Alzheimer’s disease and PPIs

Researchers conclude that there is no clinically meaningful association between PPI use and risk of Alzheimer’s disease.

MRI scan of brain showing Alzheimer's disease
Using national data from Finland, researchers found no link between proton pump inhibitor use and risk of Alzheimer's disease

Shutterstock.com

Some research has indicated that proton pump inhibitor (PPI) use could increase the risk of dementia.

In a recent study, researchers used national data from Finland to conduct a case-control study of 70,718 people newly diagnosed with Alzheimer’s disease (AD) and 282,858 matched controls.

They found no link between PPI use and risk of AD when they examined a three-year window between exposure and outcome — to reduce the risk of reverse causation (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00–1.05). They also found no link between PPI dosage or duration of exposure and AD diagnosis.

Reporting in the American Journal of Gastroenterology (11 July 2017), the team said the results provide no evidence of a clinically meaningful association between PPI use and risk of AD[1]
.

References

[1] Taipale H, Tolppanen A-M, Tiihonen M et al. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol 2017. doi: 10.1038/ajg.2017.196

Last updated
Citation
Clinical Pharmacist, CP, October 2017, Vol 9, No 10;():DOI:10.1211/PJ.2017.20203558

You may also be interested in